(NASDAQ: LGVN) Longeveron's forecast annual revenue growth rate of 157.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.84%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.94%.
Longeveron's revenue in 2024 is $709,000.On average, 1 Wall Street analysts forecast LGVN's revenue for 2024 to be $1,206,461, with the lowest LGVN revenue forecast at $1,206,461, and the highest LGVN revenue forecast at $1,206,461. On average, 1 Wall Street analysts forecast LGVN's revenue for 2025 to be $502,692, with the lowest LGVN revenue forecast at $502,692, and the highest LGVN revenue forecast at $502,692.
In 2027, LGVN is forecast to generate $36,445,170 in revenue, with the lowest revenue forecast at $36,445,170 and the highest revenue forecast at $36,445,170.